ANZCTR search results

This study is a stepped wedge randomised controlled trial aimed at investigating the implementation and clinical effectiveness of multidisciplinary post-discharge bundles on preventing readmission for older people transitioning from hospital to residential aged care for the first time. This will be carried out at multiple hospital sites in three local health networks in South Australia. Eligible patients will be stratified according to their risk of readmission and will receive a customized post-discharge bundle of interventions based on their assessed risk. The outcomes are 30- and 90- day readmissions after the index discharge and length of stay out of hospital. Process evaluation will include the acceptability, adoption, feasibility and fidelity of implementation.

The aim of this study is to determine the feasibility of giving ketone bodies in the form of dietary supplementation to patients with acute neurological injury admitted to ICU in order to improve neurological outcomes. This study will use be a randomised controlled trial, a well known study design that eliminates study biases that can confound findings as much as possible in order to determine the true utility of the use of ketones in brain injury. Patients who are in a coma with an acute brain injury, admitted to ICU, will be eligible to participate in this trial. Participants will be randomised (like the toss of a coin) to routine administration of ketone bodies via a feeding tube on admission and standard care, or placebo and standard care alone. Ketone body supplementation is currently not available for ICU patients and will only be available within this trial. Determining the feasibility of giving ketone bodies to patients with acute brain injury admitted to ICU is the first important step in a program of research that ultimately aims to test the efficacy of using ketone bodies in this group of patients to improve neurological outcomes and reduce disability.

We want to test smart shoes. We want to see if wearing these shoes decreases falls for people with Parkinson’s disease. We can monitor your walking at home when you wear these shoes. In this project we want to test a new way of obtaining objective measures of walking and falls risk in people with Parkinson’s Disease using novel technologies allowing continuous monitoring at home. For this pilot study we want to test the usefulness of such an approach using newly developed smart shoes (‘NUSHUs’, developed by our industry partner Magnes AG) with built-in sensors that study participants can use for walking or exercising at home. These shoes are not approved by the TGA in Australia. The shoes continuously record your mobility. The smart shoes collect data while you are walking or exercising and processes the data using advanced methods. During the study you will receive a training program tailored specifically to your individual needs to complete while wearing the smart shoes. The collected data can be accessed by the treating team so they can track your progress and guide you further via telehealth or in person reviews. By understanding how such a technique can be incorporated into clinical practice, this research will contribute to exploring modern management approaches for patients suffering from Parkinson’s Disease.

This study aims to examine the effectiveness of a practice change intervention (IMPACT- CVD in CANCER clinic) in increasing the proportion of patients with cancer who receive complete baseline CV risk assessment and guideline-directed management, and guideline- directed surveillance. Who is it for? You may be eligible to participate in this study if you are patients aged 18 years or over, and diagnosed with cancer; and are about to start cancer treatment with medications that are known to, or thought to, increase risk of heart disease. Study details Participants included in this study may either have their baseline cardiovascular risk assessment conducted as per usual practice, or with a structured cardiovascular risk assessment tool and nurse-led cardiology clinic that is being tested for this study. The risk assessment that participants receive will depend upon the hospital they are being treated at and the timing of their appointments; as all participating hospitals will be allocated to start using the new clinic and cardiovascular risk assessment at different times throughout the study. All participants will receive the best standard of care regardless of whether the hospital they are attending has been allocated to use the new nurse-led clinic or not. Participants may be asked to complete three 15-minute surveys (at baseline, at 6 months, and 12 months after their cancer treatment). It is hoped that the results of this trial will help improve the experiences of care for patients receiving cancer treatment. This study seeks to find out if the cardiovascular risk assessments and education clinic helps improve the experiences of care for patients receiving cancer treatment.

This trial investigates the impact of daily consumption of two apples or two pears on cardiometabolic disease risk factors, biochemical (fingerprints) changes, and microbiome function. Adult volunteers at risk of developing cardiometabolic disease are eligible for this study. Participants will be randomly assigned to consume apples for 8 weeks, followed by a 4-week washout period, and then another 8 weeks of pears, or vice versa. It is hoped that this study will support improved health outcomes from consuming apples or pears.

This study aims to evaluate a new method, the IRIS protocol, for administering drug provocation tests to patients with suspected drug allergies during surgery. The IRIS protocol gradually increases the drug dosage more slowly than the standard method, potentially reducing the risk of severe allergic reactions. We hypothesize that the IRIS protocol will result in lower drug doses at the time a reaction is detected, making it a safer alternative to current practices.

The study has two parts: A and B. This information is for part B. Part B of the study will test the safety and efficacy of giving 4 doses of fludrocortisone (study drug) to people with geographic atrophy (GA), which is an advanced form of age-related macular degeneration (AMD). Age-related macular degeneration (AMD) is a disease of the macula, an area in the retina found at the back of the eye, needed for sharp, clear vision and activities such as reading and sewing. The advanced form of dry AMD is known as geographic atrophy (GA) (a region of the retina where the cells wither away and die). Sometimes, these regions of GA look like a map to the doctor who is examining the retina, hence the term “geographic atrophy.” The purpose of this study is whether fludrocortisone (study drug) is safe to give to people with GA and if it can prevent or slow down the progression of GA.

OA is a condition that affects the joints and causes pain and stiffness. In Australia, around three million people have OA, but the way we currently treat OA isn't always based on the best evidence. Sometimes, the care is not well coordinated, not very helpful, or not suitable for the person's needs. The COASTAL study is a research study testing three different ways of providing this care: in-person (face-to-face), or through technology like telehealth (video or phone calls) or using an online app. This research study will compare how well these different programs work at improving pain for people with knee OA. We hope the results of this study will help policymakers and healthcare providers decide on the best way to organise services for people with knee OA. We hypothesise that the three methods of delivering knee OA management programs will be non-inferior to each other for reducing average knee pain on walking.

Transplantation of initially unsuitable livers following extended organ perfusion is an open-label, non-randomised, prospective, single-arm trial, using normothermic extended organ perfusion to test viability and then transplant marginal livers. It will be conducted at the Australian National Liver Transplant Unit (ANLTU) at Royal prince Alfred Hospital.

Atrial Fibrillation (AF) remains the most prevalent heart rhythm disorder. AF causes morbidity and mortality, and also a negative effect on human sexual function. Furthermore, catheter ablation is an effective method of AF treatment, and the influence it has on human sexual function is unclear. This study hypothesises that catheter ablation will have a positive effect on human sexual function. This study aims to describe the effect of catheter ablation on human sexual function.